The Pathogenic Role of the Adaptive Immune Response to Modified LDL in Diabetes
Authors:
Open Access
- 1 January 2012
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 3, 26255
Abstract
The main causes of morbidity and mortality in diabetes are macro and microvascular complications, including atherosclerosis, nephropathy, and retinopathy. As the definition of atherosclerosis as a chronic inflammatory disease became widely accepted, it became important to define the triggers of vascular inflammation. Oxidative and other modifications of lipids and lipoproteins emerged as major pathogenic factors in atherosclerosis. Modified forms of LDL (mLDL) are pro-inflammatory by themselves, but, in addition, mLDLs including oxidized, malondialdehyde (MDA)-modified, and advanced glycation end (AGE)-product-modified LDL induce autoimmune responses in humans. The autoimmune response involves T cells in the arterial wall and synthesis of IgG antibodies. The IgG auto-antibodies that react with mLDLs generate immune complexes (IC) both intra and extravascularly, and those IC activate the complement system as well as phagocytic cells via the ligation of Fcγ receptors. In vitro studies proved that the pro-inflammatory activity of IC containing mLDL (mLDL-IC) is several-fold higher than that of the modified LDL molecules. Clinical studies support the pathogenic role of mLDL-IC in the development of macrovascular disease patients with diabetes. In type 1 diabetes, high levels of oxidized and AGE-LDL in IC were associated with internal carotid intima-media thickening and coronary calcification. In type 2 diabetes, high levels of MDA-LDL in IC predicted the occurrence of myocardial infarction. There is also evidence that mLDL-IC are involved in the pathogenesis of diabetic nephropathy and retinopathy. The pathogenic role of mLDL-IC is not unique to diabetic patients, because those IC are also detected in non-diabetic individuals. But mLDL-IC are likely to reach higher concentrations and have a more prominent pathogenic role in diabetes due to increased antigenic load secondary to high oxidative stress and to enhanced autoimmune responses in type 1 diabetes.Keywords
This publication has 89 references indexed in Scilit:
- High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetesNephrology Dialysis Transplantation, 2011
- Lipoprotein associated phospholipase A2: role in atherosclerosis and utility as a biomarker for cardiovascular riskEPMA Journal, 2011
- Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetesAtherosclerosis, 2010
- Heat Shock Protein 70B′ (HSP70B′) Expression and Release in Response to Human Oxidized Low Density Lipoprotein Immune Complexes in MacrophagesJournal of Biological Chemistry, 2010
- Fcγ Receptor Cross-linking Stimulates Cell Proliferation of Macrophages via the ERK PathwayJournal of Biological Chemistry, 2010
- Clinical significance of the humoral immune response to modified LDLClinical Immunology, 2010
- CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimerNature Immunology, 2009
- Lipoprotein Accumulation in Macrophages via Toll-Like Receptor-4–Dependent Fluid Phase UptakeCirculation Research, 2009
- Oxidized LDL immune complexes and oxidized LDL differentially affect the expression of genes involved with inflammation and survival in human U937 monocytic cellsAtherosclerosis, 2009
- Signal Transducer and Activator of Transcription-1 Is Critical for Apoptosis in Macrophages Subjected to Endoplasmic Reticulum Stress In Vitro and in Advanced Atherosclerotic Lesions In VivoCirculation, 2008